000212552 001__ 212552
000212552 005__ 20240229154914.0
000212552 0247_ $$2doi$$a10.1002/ijc.34449
000212552 0247_ $$2pmid$$apmid:36715363
000212552 0247_ $$2ISSN$$a0020-7136
000212552 0247_ $$2ISSN$$a1097-0215
000212552 0247_ $$2altmetric$$aaltmetric:141974028
000212552 037__ $$aDKFZ-2023-00237
000212552 041__ $$aEnglish
000212552 082__ $$a610
000212552 1001_ $$aMao, Ziling$$b0
000212552 245__ $$aPre-diagnostic Serum Glyceraldehyde-Derived Advanced Glycation End Products and Mortality Among Colorectal Cancer Patients.
000212552 260__ $$aBognor Regis$$bWiley-Liss$$c2023
000212552 3367_ $$2DRIVER$$aarticle
000212552 3367_ $$2DataCite$$aOutput Types/Journal article
000212552 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681198925_5541
000212552 3367_ $$2BibTeX$$aARTICLE
000212552 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000212552 3367_ $$00$$2EndNote$$aJournal Article
000212552 500__ $$a2023 Jun 1;152(11):2257-2268
000212552 520__ $$aGlyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1,034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 =1.53, 95%CI: 1.04-2.25, Ptrend =0.002) and all-cause (HRQ5 vs Q1 =1.62, 95%CI: 1.16-2.26, Ptrend <0.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon =1.02, 95%CI: 0.74-1.42; HRdistal colon =1.51, 95%CI: 1.20-1.91; Peffect modification =0.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR=1.78, 95%CI: 1.02-3.01) and all-cause mortality (HR=2.15, 95%CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that pre-diagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted. This article is protected by copyright. All rights reserved.
000212552 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000212552 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000212552 650_7 $$2Other$$aGlyceraldehyde-derived advanced glycation end products
000212552 650_7 $$2Other$$aadvanced glycation end products
000212552 650_7 $$2Other$$acolorectal cancer
000212552 650_7 $$2Other$$amortality
000212552 650_7 $$2Other$$aprospective study
000212552 7001_ $$aBaker, Jacqueline Roshelli$$b1
000212552 7001_ $$aTakeuchi, Masayoshi$$b2
000212552 7001_ $$aHyogo, Hideyuki$$b3
000212552 7001_ $$aTjønneland, Anne$$b4
000212552 7001_ $$aEriksen, Anne Kirstine$$b5
000212552 7001_ $$00000-0001-7157-419X$$aSeveri, Gianluca$$b6
000212552 7001_ $$aRothwell, Joseph$$b7
000212552 7001_ $$aLaouali, Nasser$$b8
000212552 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b9$$udkfz
000212552 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b10$$udkfz
000212552 7001_ $$aSchulze, Matthias B$$b11
000212552 7001_ $$00000-0002-5558-2437$$aPalli, Domenico$$b12
000212552 7001_ $$00000-0001-5201-172X$$aSieri, Sabina$$b13
000212552 7001_ $$ade Magistris, Maria Santucci$$b14
000212552 7001_ $$aTumino, Rosario$$b15
000212552 7001_ $$00000-0002-8008-5096$$aSacerdote, Carlotta$$b16
000212552 7001_ $$aDerksen, Jeroen W G$$b17
000212552 7001_ $$00000-0002-0031-4152$$aGram, Inger T$$b18
000212552 7001_ $$aSkeie, Guri$$b19
000212552 7001_ $$aSandanger, Torkjel M$$b20
000212552 7001_ $$aQuirós, Jose Ramón$$b21
000212552 7001_ $$aCrous-Bou, Marta$$b22
000212552 7001_ $$aSánchez, Maria-Jose$$b23
000212552 7001_ $$aAmiano, Pilar$$b24
000212552 7001_ $$aColorado-Yohar, Sandra M$$b25
000212552 7001_ $$aGuevara, Marcela$$b26
000212552 7001_ $$00000-0001-8540-6891$$aHarlid, Sophia$$b27
000212552 7001_ $$aJohansson, Ingegerd$$b28
000212552 7001_ $$aPerez-Cornago, Aurora$$b29
000212552 7001_ $$00000-0001-8648-4998$$aFreisling, Heinz$$b30
000212552 7001_ $$aGunter, Marc$$b31
000212552 7001_ $$aWeiderpass, Elisabete$$b32
000212552 7001_ $$00000-0001-6517-1300$$aHeath, Alicia K$$b33
000212552 7001_ $$00000-0002-0442-3284$$aAglago, Elom$$b34
000212552 7001_ $$00000-0002-0573-1852$$aJenab, Mazda$$b35
000212552 7001_ $$00000-0002-7805-9913$$aFedirko, Veronika$$b36
000212552 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34449$$gp. ijc.34449$$n11$$p2257-2268$$tInternational journal of cancer$$v152$$x0020-7136$$y2023
000212552 909CO $$ooai:inrepo02.dkfz.de:212552$$pVDB
000212552 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000212552 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000212552 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000212552 9141_ $$y2023
000212552 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-25$$wger
000212552 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000212552 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000212552 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000212552 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000212552 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000212552 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000212552 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000212552 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000212552 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000212552 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000212552 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000212552 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000212552 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000212552 980__ $$ajournal
000212552 980__ $$aVDB
000212552 980__ $$aI:(DE-He78)C020-20160331
000212552 980__ $$aUNRESTRICTED